In the tumor core, we found that the CLDN18.2-positive group showed significantly higher total number of CD8+ T, CD8+LAG-3− T, CD8+PD-1− T, and CD8+TIM-3− T cells than in the CLDN18.2-negative group. This evidence concerns the gene STMN1 and neoplasm.